Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

Policlinico Universitario Campus Biomedico Di Roma, Roma

Montefiore Einstein Cancer Center, The Bronx

Clinical Research Alliance, Lake Success

State University of New York Upstate Medical Center, Syracuse

Roswell Park Cancer Institute, Buffalo

Hospital Universitario a Coruna, A Coruña

Azienda Ospedaliera Universitaria San Martino, Genova

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

CHRU Besancon, Besançon

Hospital Clinico San Carlos, Madrid

Levine Cancer Institute, Charlotte

Cancer Treatment Centers of America - Southeastern Regional Medical Center, Newnan

Piedmont Cancer Institute PC, Atlanta

Florida Hospital Cancer Institute, Orlando

Hopital Haut Leveque, Pessac

Hospital Universitario Marques de Valdecilla, Santander

Mark H Zangmeister Center, Columbus

Saint Joseph Mercy Ann Arbor Hospital, Ann Arbor

Karmanos Cancer Center Wayne State University, Detroit

Centre Regional de lutte contre le cancer Paul Papin, Angers

Hospital Miguel Servet, Zaragoza

Hopital Saint Antoine, Paris

Houston Methodist Cancer Center, Houston

Ospedale Sacro Cuore di Gesu FatebeneFratelli, Benevento

Mayo Clinic - Arizona, Scottsdale

Scripps Clinic Torrey Pines, San Diego

UC Davis Cancer Center, Sacramento

Smilow Cancer Hospital At Yale-New Haven, New Haven

ME Center for Cancer Medicine, Scarborough

Tufts - New England Medical Center, Boston

University of Massachusetts, Worcester

Dartmouth Hitchcock Medical Center, Lebanon

Regional Cancer Care Associates LLC, Morristown

Vanderbilt University Medical Center, Nashville

Tom Baker Cancer Center, Calgary

Cross Cancer Institute, Edmonton

British Columbia Cancer Agency, Vancouver

CHUM Hôpital Saint-Luc, Montreal

McGill University, Montreal

Centre Hospitalier Belfort Montbeliard, Besançon

Hopital Beaujon, Clichy

ICO-Hospital Germans Trias i Pujol, Barcelona